InMed Pharmaceuticals (OTCQX: IMLFF), (TSX:IN) is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our robust microbial-based biosynthesis process designed to enable the manufacturing of a wide range of cannabinoids typically found in trace amounts from natural sources.
InMed’s cannabinoid compounds are designed to be bio-identical to the naturally-occurring cannabinoids. The process is envisioned to offer cost and time savings and superior ease, control and quality of manufacturing when compared to alternative methods.